Skip to main content
. 2017 Sep 11;8(51):88658–88669. doi: 10.18632/oncotarget.20809

Figure 5. LncRNA uc.57 overexpression reduces in vitro and in vivo TAM resistance in MCF-7R cells.

Figure 5

(A) CCK8 assay showing cell viability of MCF-7R-lv-NC and MCF-7R-lv-uc.57 cells treated with or without 0.1 µM TAM. (B) Representative image showing tumors from xenografted MCF-7R-lv-uc.57 cells in human breast tissue-derived mouse model. (C) Representative images showing tumors from TAM treated mice xenografted with MCF-7R-lv-NC and MCF-7R-lv-uc.57 cells in human breast tissue-derived mouse model at 4 weeks after implantation. (D) Tumor growth curves of TAM treated mice xenografted with MCF-7R-lv-NC and MCF-7R-lv-uc.57 cells in human breast tissue-derived mouse model. Note: *denotes P < 0.05 compared to control.